Abstract
Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of colon cancer cells in vitro and have been studied as chemo-preventative agents in clinical trials; their effects on colon cancer cells may result from effects distinct from inhibition of cyclooxygenase (Cox)-2. Genetic mutations leading to the accumulation of β-catenin occur in the majority of colorectal cancers. One of the critical pathways targeted by NSAIDs is the down-regulation of β-catenin expression. The mechanism by which NSAIDs down-regulate β-catenin has not been defined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
